InspireMD, Inc. (NSPR) - Dilution Analysis

10-Q filing | 46.8M shares outstanding

8-K filing: InspireMD, Inc. entered into an Equity Distribution Agreement with BTIG, LLC to offer and sell up to $75,000,000 of shares of the Company's common stock and terminated a previous agreement with Piper Sandler & Co.

10-K filing | 46.8M shares outstanding

10-Q filing | 42.4M shares outstanding

S-3 filing: Resale of common stock by selling stockholders.

10-Q filing | 41.7M shares outstanding

8-K filing: InspireMD, Inc. entered into a securities purchase agreement for a private placement offering of 6,791,380 common shares and pre-funded warrants to purchase up to 9,764,804 common shares, with gross proceeds of approximately $40.1 million expected to close on August 1, 2025, and also announced the completion of the full exercise of 12.9 million Series I warrants converted into 2,352,393 common shares and 10,561,685 pre-funded warrants with gross proceeds of approximately $17.9 million. ($58.0M proceeds)

10-Q filing | 30.6M shares outstanding

S-3 filing: The filing is an S-3 form for an at-the-market offering of common stock with a proposed amount of up to $75,000,000. The offering will be made through Piper Sandler, with the net proceeds used for general corporate purposes.

10-K filing | 29.7M shares outstanding

10-Q filing | 26.1M shares outstanding

10-Q filing | 25.7M shares outstanding

8-K filing: The Company announced the completion of the full exercise of 12.9 million of the Company's Series H warrants, resulting in the conversion into 292,996 of common shares and 12,599,343 of pre-funded warrants, with gross proceeds of $17.9 million. ($17.9M proceeds)

10-Q filing | 24.9M shares outstanding

10-K filing | 24.3M shares outstanding

10-Q filing | 21.5M shares outstanding

10-Q filing | 21.1M shares outstanding

S-3 filing: This S-3 filing registers for resale up to 77,484,492 shares of common stock held by selling stockholders, consisting of shares, pre-funded warrant shares, and warrant shares, issued pursuant to a private placement transaction consummated on May 16, 2023.

8-K filing: InspireMD, Inc. entered into a securities purchase agreement to sell and issue 10,266,270 shares of common stock, pre-funded warrants to purchase up to 15,561,894 shares of common stock, and warrants to purchase up to 51,656,328 shares of common stock in a private placement offering at a price of $1.6327 per share and associated warrants and $1.6326 per pre-funded warrant and associated warrants, with gross proceeds of approximately $42.2 million expected to close on or about May 15, 2023. ($42.2M proceeds)

10-Q filing | 8.1M shares outstanding

10-K filing | 7.9M shares outstanding

10-Q filing | 7.8M shares outstanding

10-Q filing | 7.8M shares outstanding

S-3 filing: InspireMD, Inc. may offer, issue and sell from time to time up to $150,000,000 of our common stock, preferred stock, subscription rights, debt securities, warrants and a combination of such securities, separately or as units, in one or more offerings.

10-Q filing | 7.8M shares outstanding

10-K filing | 8.3M shares outstanding

10-Q filing | 8.1M shares outstanding

10-Q filing | 7.9M shares outstanding

10-Q filing | 3.3M shares outstanding

S-3 filing: InspireMD, Inc. is offering up to 1,341,682 shares of its common stock by a selling stockholder, who received these shares in a private placement transaction on February 5, 2021, to satisfy a covenant in the investor rights agreement.

10-K filing | 38.4M shares outstanding

8-K filing: InspireMD, Inc. completed a public offering of 29,032,258 units at $0.62 per unit on February 8, 2021, with each unit comprising one share of common stock and one Series G warrant, and the underwriter fully exercised its option to purchase an additional 4,354,838 units. ($20.17M proceeds)

S-1/A filing: InspireMD, Inc. is offering 19,677,292 units, each consisting of one share of common stock and/or one Series G Warrant to purchase one half of one share of common stock, and pre-funded units. The company intends to use the net proceeds of this offering to fund its anticipated pivotal clinical trials in connection with its CGuard™ Carotid Stent System, CARENET-III for the prevention of stroke caused by carotid artery disease (CAD) including the costs of producing and manufacturing the product required for the trial and enhancements to our manufacturing and quality systems for purposes of compliance with FDA Good Manufacturing Practices (GMP) and for working capital and general corporate purposes.

8-K filing: InspireMD, Inc. entered into a Distribution Agreement with China-based partners for exclusive distribution rights in China and also entered into a Securities Purchase Agreement with QIDI Asia Medical Limited to issue and sell 1,341,682 shares of common stock at $0.6708 per share for $900,000. ($0.9M proceeds)

S-1/A filing: This S-1/A filing, dated 2021-01-29, relates to an offering of 19,677,292 units, pre-funded units, and related Series G Warrants for shares of common stock, as well as updates on recent company developments including ATM offering and other general corporate matters.

S-1 filing: The company is offering shares of its common stock and pre-funded warrants to purchase common stock.

10-Q filing | 3.9M shares outstanding

8-K filing: InspireMD, Inc. appointed Andrea Tommasoli as Senior Vice President of Global Sales and Marketing and granted him 271,534 shares of restricted stock and options to purchase 90,511 shares of common stock as inducement awards.

8-K filing: InspireMD, Inc. consummated a private placement issuing 222,223 shares of common stock to Dr. Gary S. Roubin at a purchase price of US$0.45 per share for an aggregate purchase price of US$100,000. ($0.1M proceeds)

8-K filing: InspireMD, Inc. appointed Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and granted him 162,920 shares of restricted stock and options to purchase 54,307 shares of the Company's common stock as inducement awards.

10-Q filing | 3.9M shares outstanding

8-K filing: InspireMD, Inc. entered into a settlement agreement with H.C. Wainwright & Co., LLC, reducing the exercise price of warrants to purchase 274,029 shares of the Company's common stock to $0.495.

8-K filing: InspireMD, Inc. completed a public offering of units and pre-funded units, along with the underwriter's option exercise, resulting in gross proceeds of approximately $11.5 million. ($11.5M proceeds)

S-1/A filing: The company is offering units, each consisting of one share of common stock and one Series F Warrant, and pre-funded units, each consisting of one pre-funded warrant and one Series F Warrant. They are also offering shares of common stock issuable upon exercise of the Series F Warrants and pre-funded warrants.

S-1/A filing: The filing is an S-1/A form for offering 11,111,111 shares of common stock and pre-funded warrants to purchase up to 11,111,111 shares of common stock.

S-1 filing: The filing relates to the offering of common stock and pre-funded warrants. The pre-funded warrants are offered to purchasers who would otherwise beneficially own more than 4.99% (or 9.99%) of the outstanding common stock after the offering.

10-Q filing | 3.9M shares outstanding

10-K filing | 0.8M shares outstanding